Adlai Nortye Ltd. American Depositary Shares (NASDAQ:ANL) — Market Cap & Net Worth
Market Cap & Net Worth: Adlai Nortye Ltd. American Depositary Shares (ANL)
Adlai Nortye Ltd. American Depositary Shares (NASDAQ:ANL) has a market capitalization of $350.92 Million ($350.92 Million) as of May 2, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #14325 globally and #3236 in its home market, demonstrating a 3.96% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Adlai Nortye Ltd. American Depositary Shares's stock price $15.50 by its total outstanding shares 31236934 (31.24 Million). Analyse cash flow conversion of Adlai Nortye Ltd. American Depositary Sh to see how efficiently the company converts income to cash.
Adlai Nortye Ltd. American Depositary Shares Market Cap History: 2023 to 2026
Adlai Nortye Ltd. American Depositary Shares's market capitalization history from 2023 to 2026. Data shows growth from $280.82 Million to $484.17 Million (1.27% CAGR).
Index Memberships
Adlai Nortye Ltd. American Depositary Shares is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.01% | #377 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1365 of 3165 |
Weight: Adlai Nortye Ltd. American Depositary Shares's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Adlai Nortye Ltd. American Depositary Shares Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Adlai Nortye Ltd. American Depositary Shares's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
56.21x
Adlai Nortye Ltd. American Depositary Shares's market cap is 56.21 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $280.82 Million | $5.00 Million | -$104.87 Million | 56.21x | N/A |
Competitor Companies of ANL by Market Capitalization
Companies near Adlai Nortye Ltd. American Depositary Shares in the global market cap rankings as of May 2, 2026.
Key companies related to Adlai Nortye Ltd. American Depositary Shares by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Adlai Nortye Ltd. American Depositary Shares Historical Marketcap From 2023 to 2026
Between 2023 and today, Adlai Nortye Ltd. American Depositary Shares's market cap moved from $280.82 Million to $ 484.17 Million, with a yearly change of 1.27%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $484.17 Million | +991.55% |
| 2025 | $44.36 Million | -47.12% |
| 2024 | $83.88 Million | -70.13% |
| 2023 | $280.82 Million | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Adlai Nortye Ltd. American Depositary Shares was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $350.92 Million USD |
| MoneyControl | $350.92 Million USD |
| MarketWatch | $350.92 Million USD |
| marketcap.company | $350.92 Million USD |
| Reuters | $350.92 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Adlai Nortye Ltd. American Depositary Shares
Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E recept… Read more